SYS6090 + bevacizumab

SYS6090 + bevacizumab is an investigational combination therapy being developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group) for the treatment of advanced or metastatic colorectal cancer, particularly in patients with mismatch repair-proficient (pMMR) or microsatellite stable (MSS) disease. SYS6090 is a recombinant humanized bispecific antibody designed with a dual mechanism of action that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). By inhibiting these two distinct immune checkpoints, SYS6090 aims to enhance T-cell activation and overcome immune tolerance within the tumor microenvironment. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing tumor angiogenesis and potentially modulating the immune environment to improve the efficacy of immunotherapy. The combination is currently being evaluated in a Phase Ib/II clinical trial (NCT06184100) to assess its safety, tolerability, and anti-tumor activity, often in further combination with chemotherapy regimens such as capecitabine and oxaliplatin.